Skip to main content

Advertisement

Log in

Locally advanced anal canal carcinoma: is the addition of cetuximab the answer?

  • Letter to the Editor
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Siegel R, Ma J, Zou Z, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29

    Article  PubMed  Google Scholar 

  2. UKCCCR Anal Cancer Trial Working Party (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 348(9034):1049–1054

    Article  Google Scholar 

  3. Bartelink H, Roelofse F, Eschwege F et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 2040–2049:15

    Google Scholar 

  4. Olivatto LO, Vieira FM, Pereira BV, Victorino AP, Bezerra M, Araujo CM, Erlich F, Faroni L, Castro L, Lusis EC, Marins A, Ferreira CG (2013) Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer 119(16):2973–2980

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no competing interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Francesca De Felice.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

De Felice, F., Musio, D. & Tombolini, V. Locally advanced anal canal carcinoma: is the addition of cetuximab the answer?. Int J Colorectal Dis 31, 751–752 (2016). https://doi.org/10.1007/s00384-015-2243-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-015-2243-5

Keywords

Navigation